What BMI Doctors sells, how the prices work, and where the pages conflict
BMI Doctors is associated with Ocenture LLC in its terms and footer. The terms also refer to BMI Doctors, Inc. and affiliated professional entities, but the public enrollment pages do not identify the professional practice that would treat an individual patient.
The care-team page names Jay Flottman, MD; Judith Germaine, MD; Melissa VanSickle, MD; Kevin Kargman, MD; Peter Nwoke, MD; Carleigh Ferrier, PA-C; and Deejay Linders, FNP-BC. BMI Doctors says its physicians are board certified. The site does not map each clinician to states, licenses, or the professional entity responsible for a given encounter.
The current product catalog resolves to four records. Manufacturer brand names are explicitly excluded because BMI Doctors says it does not provide Rybelsus, Ozempic, Wegovy, Zepbound, or Mounjaro. Dose tiers, needles, laboratory services, and family telemedicine access do not become therapies.
Semaglutide injection has two comparable plan terms: $747 for three months and $279 for one month. Their effective monthly rates are $249 and $279, producing the displayed average of $264 per month. The three-month plan therefore requires materially more cash upfront than the card headline.
Injectable tirzepatide is $990 for three months or $470 for one month. Averaging the $330 and $470 effective monthly rates produces $400 per month. A patient should verify the first charge, renewal schedule, dose, formula, and quantity in checkout before paying.
Oral semaglutide drops repeat the $747 three-month and $279 one-month terms, so the same $264 average applies. These drops are not Rybelsus tablets, and BMI Doctors' own educational material says published evidence for compounded semaglutide drops is sparse.
Oral tirzepatide is shown at $349 for one month. A three-month block appears under the same heading at $249 per month, but its bullets say semaglutide medication is included. The card excludes that row, because correcting a likely template mistake editorially would create an unsupported promise.
The oral-tirzepatide page says its compounded drops aim to provide effects similar to injectable tirzepatide. Another BMI Doctors article says specific trials for tirzepatide drops have not been publicly reported. This review does not transfer injection trial results to the sublingual product.
BMI Doctors says its compounded semaglutide injection is often combined with cyanocobalamin, but the sales page does not establish whether every vial contains B12. The exact label, active ingredients, salt or base, concentration, additives, dosing units, and pharmacy should be confirmed for each prescription.
The sales flow starts with intake, then a Quest Diagnostics requisition, laboratory completion, and a one-on-one clinician visit. A clinician must determine that pharmacotherapy is appropriate before prescribing. The plan price is advertised as including the initial lab work, visit, medication, and delivery.
The qualification quiz requires age 18 or older and a BMI greater than 27 and screens out Type 1 diabetes, active eating disorder, pregnancy or planned pregnancy, breastfeeding, active gallbladder disease, recent or GLP-1-associated pancreatitis, recent bariatric surgery, active substance misuse, active cancer treatment, and medullary thyroid cancer or MEN syndrome.
A separate exclusions page conflicts with the quiz by listing both Type 1 and Type 2 diabetes among exclusions while elsewhere saying Type 2 diabetes may support eligibility. The treating clinician and current intake, not a static marketing article, control eligibility.
BMI Doctors advertises service in 41 states and places its coverage in a map rather than a readable text list. The terms say availability depends on location. Patients should confirm the chosen product, clinician license, laboratory access, and pharmacy shipment in checkout.
Medication is shipped from an unnamed partner pharmacy. The main plan pages promise no-charge second-day air, while the semaglutide pricing FAQ describes UPS overnight cold-packed delivery and quarterly three-month shipments. Neither page names the pharmacy or supplies a universal dispatch-time commitment.
The terms call the program membership based and automatically recurring, even though sales pages repeatedly say no membership fees and no contracts. They also describe monthly card charges, while the three-month plans advertise quarterly prepayment. Those mechanics need confirmation before purchase.
Cancellation is available through the portal, phone, or email and is said to take effect within 36 hours. The terms say service continues through the last paid monthly billing cycle, but they do not explain how that language applies to a prepaid three-month shipment or unused medication.
The refund page says most fees are nonrefundable and opened or used medication cannot be returned. A full refund is offered when a clinician determines the patient is not an appropriate candidate. The page expressly names semaglutide, while broader sales copy also references tirzepatide, creating another policy mismatch.
Federal shortage-based enforcement discretion for compounded semaglutide and tirzepatide injections has ended. This does not make every patient-specific compound unlawful, but it makes the unnamed pharmacy, exact formula, patient-specific clinical difference, and legal basis important questions. Compounded products do not undergo FDA premarket approval.
BMI Doctors' privacy page says it covers only online information and carries a modification date that substantially predates the current treatment program, while the separate HIPAA notice governs protected health information for affiliated practices. The public site uses analytics and advertising tools, and the consumer privacy policy appears materially stale.
Awin advertiser 51411 remains pending. The stored commercial record reports 7% per approved sale, a public average order value of $747, and 30-day attribution. No tracking URL is approved, and neither commission nor the public first-month coupon affects the editorial score.
- Four cards cover two ingredients and two administration routes without counting manufacturer brands.
- Three defensible cards use compact multi-plan monthly averages; oral tirzepatide uses only its reliable one-month price.
- The $249 rate requires a $747 three-month prepayment, and injectable tirzepatide's $330 rate requires $990.
- Quest laboratory work, a clinician consultation, medication, and shipping are advertised as bundled.
- The site names seven clinicians but not the assigned professional entity or dispensing pharmacy.
- Marketing and legal pages conflict on membership, billing cadence, support hours, eligibility, and company address.
- The oral-tirzepatide page advertises a dosage form while another BMI Doctors article acknowledges the absence of comparable published trials.
- Compounded GLP-1 products are not FDA approved, and shortage-based enforcement discretion has ended.
- Affiliate economics are excluded from the editorial score and the CTA remains untracked.
